Abstract
Purpose
The optimal surgical approach to extensive Crohn’s disease (CD) terminal ileitis is debated. To date, no studies have directly compared the short- and long-term outcomes of modified side-to-side isoperistaltic strictureplasty over the valve (mSSIS) to traditional ileocecal resection.
Methods
A retrospective, observational, comparative study was conducted in consecutive CD patients operated for extensive involvement of the terminal ileum (≥ 20 cm). Ninety-day postoperative morbidity was assessed using the comprehensive complication index (CCI). Surgical recurrence was defined as the need for any surgical intervention related to CD during the follow-up period. Endoscopic remission was defined as ≤ i2a, according to the modified Rutgeerts score. Deep remission was defined as the combination of endoscopic remission and absence of clinical symptoms. Perioperative factors related to clinical recurrence were evaluated.
Results
Eighty-seven patients were included (47 (54%) ileocecal resection and 40 (46%) mSSIS). Median follow-up was 56 (IQR 34.7–94.4) and 72 (IQR 48.3–87.2) months for resection and mSSIS, respectively (p < 0.001). No mortality occurred. Mean CCI was 9.1 vs 8.5 for ileocecal resection and mSSIS, respectively (p = 0.48). Throughout the follow-up, 8 patients in the resection group (17%) and 5 patients in the mSSIS group (12.5%) experienced surgical recurrence (p = 0.393). Thirty-seven (92.5%) of patients kept the mSSIS. No difference in deep remission was observed (41% vs 22.5%, p = 0.34).
Conclusions
Modified SSIS seems to be non-inferior in terms of safety, recurrence, and durability to traditional resections with the advantage of mitigating the risk of a short bowel syndrome. Larger prospective studies are required to confirm these findings.
Similar content being viewed by others
Data availability
Institutional database
References
Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L (2012) Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther 35(6):625–633
Frolkis AD, Lipton DS, Fiest KM, Negron ME, Dykeman J, de Bruyn J et al (2014) Cumulative incidence of second intestinal resection in Crohn’s disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol 109(11):1739–1748
Gklavas A, Dellaportas D, Papaconstantinou I (2017) Risk factors for postoperative recurrence of Crohn’s disease with emphasis on surgical predictors. Ann Gastroenterol 30(6):598–612
Bernell O, Lapidus A, Hellers G (2000) Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn’s disease. Br J Surg 87(12):1697–1701
Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, Doherty G, el-Hussuna A, Ellul P, Fiorino G, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gisbert JP, Gomollon F, González Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Kucharzik T, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Stassen L, Torres J, Uzzan M, Vavricka S, Verstockt B, Zmora O (2020) ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis. 14(2):155–168
Michelassi F (1996) Side-to-side isoperistaltic strictureplasty for multiple Crohn’s strictures. Dis Colon Rectum 39(3):345–349
Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 55(6):749–753
de Buck van Overstraeten A, Vermeire S, Vanbeckevoort D, Rimola J, Ferrante M, Van Assche G et al (2016) Modified side-to-side isoperistaltic strictureplasty over the ileocaecal valve: an alternative to ileocaecal resection in extensive terminal ileal Crohn’s disease. J Crohns Colitis. 10(4):437–442
Riviere P, Vermeire S, Irles-Depe M, Van Assche G, Rutgeerts P, de Buck van Overstraeten A et al (2019) No change in determining Crohn’s disease recurrence or need for endoscopic or surgical intervention with modification of the Rutgeerts’ Scoring System. Clin Gastroenterol Hepatol 17(8):1643–1645
Clavien PA, Vetter D, Staiger RD, Slankamenac K, Mehra T, Graf R, Puhan MA (2017) The Comprehensive Complication Index (CCI(R)): added value and clinical perspectives 3 years “down the line”. Ann Surg 265(6):1045–1050
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
Stein K, Hieggelke L, Schneiker B, Lysson M, Stoffels B, Nuding S, Wehkamp J, Kikhney J, Moter A, Kalff JC, Wehner S (2018) Intestinal manipulation affects mucosal antimicrobial defense in a mouse model of postoperative ileus. PLoS One 13(4):e0195516
de Buck van Overstraeten A, Eshuis EJ, Vermeire S, Van Assche G, Ferrante M, D’Haens GR et al (2017) Short- and medium-term outcomes following primary ileocaecal resection for Crohn’s disease in two specialist centres. Br J Surg 104(12):1713–1722
D’Haens GR, Gasparaitis AE, Hanauer SB (1995) Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn’s disease. Gut. 36(5):715–717
Coffey CJ, Kiernan MG, Sahebally SM, Jarrar A, Burke JP, Kiely PA, Shen B, Waldron D, Peirce C, Moloney M, Skelly M, Tibbitts P, Hidayat H, Faul PN, Healy V, O’Leary PD, Walsh LG, Dockery P, O’Connell RP, Martin ST, Shanahan F, Fiocchi C, Dunne CP (2018) Inclusion of the mesentery in ileocolic resection for Crohn’s disease is associated with reduced surgical recurrence. J Crohns Colitis 12(10):1139–1150
Rivera ED, Coffey JC, Walsh D, Ehrenpreis ED (2019) The mesentery, systemic inflammation, and Crohn’s disease. Inflamm Bowel Dis 25(2):226–234
Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R et al (1991) Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet. 338(8770):771–774
Komatsu S, Nimura Y, Granger DN (1999) Intestinal stasis associated bowel inflammation. World J Gastroenterol 5(6):518–521
Fazi M, Giudici F, Luceri C, Pronesti M, Tonelli F (2016) Long-term results and recurrence-related risk factors for Crohn disease in patients undergoing side-to-side isoperistaltic strictureplasty. JAMA Surg 151(5):452–460
Michelassi F, Mege D, Rubin M, Hurst RD (2020) Long-term results of the side-to-side isoperistaltic strictureplasty in Crohn disease: 25-year follow-up and outcomes. Ann Surg 272(1):130–137
Bislenghi G, Ferrante M, Sabino J, Verstockt B, Martin-Perez B, Fieuws S, Wolthuis A, Vermeire S, D’Hoore A (2020) Short- and long-term outcomes following side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohn’s ileitis. J Crohns Colitis. 14:1378–1384
Rottoli M, Tanzanu M, Manzo CA, Bacchi Reggiani ML, Gionchetti P, Rizzello F, Boschi L, Poggioli G (2020) Strictureplasty for Crohn’s disease of the small bowel in the biologic era: long-term outcomes and risk factors for recurrence. Tech Coloproctol 24:711–720
Acknowledgments
Marc Ferrante and Severine Vermeire are senior clinical investigators of the Research Foundation Flanders (FWO).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This research study was conducted retrospectively from data obtained for clinical purposes with all the procedures being performed were part of the routine care. Approval was obtained from the ethics committee of University of Leuven (S53684).
All patients had consented for their data to be analyzed through the VLECC Biobank (Vlaamse Erfelijkheidsstudie Crohn’s en Colitis Ulcerosa, of Flemish Study for Genetics Research on Crohn’s Disease and Ulcerative Colitis).
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. Further, all the possible conflicts of interest are now disclosed:
Marc Ferrante:
Research grant: Amgen, Biogen, Janssen, Pfizer, Takeda
Consultancy: Abbvie, Boehringer-Ingelheim, Janssen, MSD, Pfizer, Sandoz, Takeda, Thermofisher
Speakers fee: Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Falk, Ferring, Janssen, Lamepro, MSD, Mylan, Pfizer, Sandoz, Takeda
Severine Vermeire:
Receipt of grants/research supports: MSD, Abbvie, Takeda, Janssen, Pfizer
Receipt of honoraria or consultation fees: AbbVie, MSD, Takeda, Ferring, Genentech/Roche, Shire, Pfizer Inc, Galapagos, Mundipharma, Hospira, Celgene, Second Genome, Progenity, Lilly, Arena, Gilead and Janssen
Participation in a company sponsored speaker’s bureau: AbbVie, MSD, Takeda, Ferring, Hospira, Pfizer, Janssen, and Tillots
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
ESM 1
(DOCX 25 kb)
Rights and permissions
About this article
Cite this article
Bislenghi, G., Fieuws, S., Wolthuis, A. et al. Positioning strictureplasty in the treatment of extensive Crohn’s disease ileitis: a comparative study with ileocecal resection. Int J Colorectal Dis 36, 791–799 (2021). https://doi.org/10.1007/s00384-021-03837-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-021-03837-6